ICU Medical

ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICU Medical reports mixed Q4 results, eyes mid-single-digit growth

ICU Medical's Q4 2022 performance showcased mixed results, with revenue declines in legacy ICU Medical offset by improvements in Infusion Systems and Vital Care at Smiths Medical.
The company provided 2023 guidance with expectations of mid-single-digit revenue growth, improved gross margin, and a focus on addressing inflationary pressures and controlling costs.
Challenges included revenue shortfalls, supply interruptions, and concerns about operating margins, while opportunities exist in addressing FX impacts, regaining lost revenues, and enhancing operational efficiency.
Overall, ICU Medical remains focused on driving business performance, maintaining customer attention, and creating value through strategic realignment and operational synergies.

ICU Medical reports robust Q1 performance amidst segment-specific challenges

ICU Medical delivered a strong Q1 performance with revenue growth across segments and improved profitability metrics, showcasing operational strength.
While facing challenges in the Vascular Access segment, the company aims for growth in Consumables and maintains a positive outlook for the year.
Opportunities for revenue growth and financial optimization through operational efficiency improvements and strategic initiatives highlight potential avenues for future success.

ICU Medical reports Q2 earnings, adjusts guidance, focuses on stability

ICU Medical's Q2 2023 earnings call highlighted financial results, ongoing integration efforts, and a focus on stability and growth. The company remains confident in recapturing market share over time and aims for a full-year gross margin target of 37%.

ICU Medical reports Q3 results, focuses on growth and efficiency

ICU Medical reported mixed Q3 2023 financial results with adjusted revenues of $547 million and a 7% decrease in GAAP revenue year-over-year.
The company demonstrated strengths in maintaining a 36% adjusted gross margin, positive free cash flow, and a focus on operational efficiency.
Challenges included revenue declines in certain business segments and the need to address analyst concerns regarding margins and revenue growth.
Opportunities lie in product innovation, cash flow optimization, and a commitment to driving revenue growth and operational efficiency for long-term success.

ICU Medical reports solid Q4 results, focuses on margin improvement

ICU Medical's Q4 performance showed revenue growth and strong cash flow, with a focus on margin improvement and revenue growth in 2024. Challenges include competitive pump market dynamics and inventory drawdown impact on margins. The company aims to capitalize on opportunities for inventory reductions and margin enhancement.

ICU Medical reports steady Q1 growth, focuses on operational efficiency

ICU Medical's Q1 2024 performance showed steady revenue growth and improved margins driven by operational efficiencies. While facing challenges in certain segments, the company's focus on quality remediation and positive free cash flow generation bode well for future stability and growth.
Strategic opportunities exist in optimizing the Vital Care segment and leveraging strengths in the Consumables business. Continued emphasis on operational efficiency and product mix could position ICU Medical for sustained success in the healthcare market.

ICU Medical posts robust Q2 results, raises full-year guidance

ICU Medical delivered a strong Q2 performance with revenue growth and margin improvement.
The company's financial health is solid, with raised full-year guidance indicating confidence in future prospects.
Challenges include managing operating expenses and sustaining growth in a competitive market.
Strategic focus on innovation and efficiency presents opportunities for continued expansion and success.

ICU Medical posts robust Q3 results, raises guidance amid JV

ICU Medical's Q3 performance reflects strength in key segments and operational efficiency.
Challenges lie in the impact of the JV on financials and liquidity concerns from outstanding AR purchases.
Opportunities abound with raised guidance, strategic JV, and positive operational updates.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICU Medical, Inc. develops, manufactures, and sells innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

ICU Medical (ICUI) delivered earnings and revenue surprises of 24.11% and 6.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates

The Company Reaffirms 2022 Fiscal Year Guidance The Company Reaffirms 2022 Fiscal Year Guidance

ICU Medical Announces Third Quarter 2022 Results

SAN CLEMENTE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2022 earnings release and conference call.

ICU Medical Announces Time of Third Quarter 2022 Earnings Conference Call

SAN CLEMENTE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference at 11:15 a.m. PT (2:15 p.m. ET) on Monday, September 12, 2022. Company management will also be participating in one-on-one meetings on Monday, September 12, 2022.

ICU Medical to Participate at the Morgan Stanley 20th Annual Global Healthcare Conference

ICU Medical, Inc. (NASDAQ:ICUI ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants John Mills - ICR Vivek Jain - CEO & Chairman Brian Bonnell - CFO & Treasurer Conference Call Participants Jayson Bedford - Raymond James & Associates Matthew Mishan - KeyBanc Lawrence Solow - CJS Securities Operator Good day, and welcome to the ICU Medical, Inc. Second Quarter 2022 Earnings Conference Call. [Operator Instructions].

ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q2 2022 Results - Earnings Call Transcript

ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates

Company Updated FY 2022 Guidance Company Updated FY 2022 Guidance

ICU Medical Announces Second Quarter 2022 Results

SAN CLEMENTE, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2022 earnings release and conference call.

ICU Medical, Inc. Announces Time of Second Quarter 2022 Earnings Conference Call

ICU Medical Inc (NASDAQ: ICUI) reported Q1 sales of $543.1 million vs. Raymond James' estimate of $530 million.

Raymond James Says 'Supply Chain Challenges Made Q1 Messy' For This Medtech Stock

ICU Medical, Inc. (NASDAQ:ICUI ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants John Mills - Managing Partner Vivek Jain - Chairman & Chief Executive Officer Brian Bonnell - Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Larry Solow - CJS Securities Matthew Mishan - KeyBanc Capital Markets Operator Greetings and welcome to the ICU Medical Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q1 2022 Results - Earnings Call Transcript

ICU Medical (ICUI) delivered earnings and revenue surprises of 1.68% and 0.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Surpasses Q1 Earnings Estimates

SAN CLEMENTE, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2022 earnings release and conference call.

ICU Medical, Inc. Announces Time of First Quarter 2022 Earnings Conference Call

ICU Medical starts off 2022 with the considerable task of integrating Smiths Medical, a $2.35B deal that significantly expands ICUI's infusion business and adds complementary assets in other departments.

ICU Medical: There Is Still Upside Here As Management Goes Big To Drive Value

Does ICU Medical (ICUI) have what it takes to be a top stock pick for momentum investors? Let's find out.

ICU Medical (ICUI) is a Great Momentum Stock: Should You Buy?

OP Bancorp

Pangaea Logistics Solutions

Meridian Bioscience

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), OP Bancorp (OPBK), ICU Medical (ICUI) and Pangaea Logistics (PANL) are well poised to gain.

Buy These 4 Low-Beta Stocks to Combat the Choppy Market

ICU Medical (ICUI) possesses solid growth attributes, which could help it handily outperform the market.

Is ICU Medical (ICUI) a Solid Growth Stock? 3 Reasons to Think " Yes "

SAN CLEMENTE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that company management will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 8:15 a.m. PT (11:15 a.m. ET) on Tuesday, March 22, 2022. Company management will also be participating in one-on-one meetings on Tuesday, March 22, 2022.

ICU Medical, Inc. to Participate at the KeyBanc Life Sciences & MedTech Investor Forum

ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice

SAN CLEMENTE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the Raymond James 43r d Annual Institutional Investors Conference at 11:15 a.m. PT (2:15 p.m. ET) on Tuesday, March 8, 2022.

ICU Medical, Inc. to Participate at the Raymond James 43rd Annual Institutional Investors Conference

ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q4 2021 Results - Earnings Call Transcript

ICU Medical (ICUI) delivered earnings and revenue surprises of 11.66% and 6.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Surpasses Q4 Earnings and Revenue Estimates

SAN CLEMENTE, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2021 earnings release and conference call.

ICU Medical Announces Time of Fourth Quarter 2021 Earnings Conference Call

3 Reasons Why ICU Medical (ICUI) Is a Great Growth Stock

SAN CLEMENTE, Calif. , Jan. 6, 2022 /PRNewswire/ -- ICU Medical Inc. (NASDAQ: ICUI) announced that it has completed its acquisition of Smiths Medical from Smiths Group plc (LSE: SMIN.L).

ICU Medical Completes the Acquisition of Smiths Medical from Smiths Group plc

SAN CLEMENTE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced that Company management will present at the J.P. Morgan 40th Annual Healthcare Conference, held virtually January 10-13, 2022.

News for ICU Medical Stock (ICUI)